Novolog Pharm-Up 1966 Ltd Reports Earnings Results for the Full Year Ended December 31, 2020 - Marketscreener.com

NVLG Stock   169.90  0.50  0.30%   
About 53% of Novolog Pharm's investor base is interested to short. The analysis of current outlook of investing in Novolog Pharm Up 1966 suggests that many traders are impartial regarding Novolog Pharm's prospects. The current market sentiment, together with Novolog Pharm's historical and current headlines, can help investors time the market. In addition, many technical investors use Novolog Pharm Up stock news signals to limit their universe of possible portfolio assets.
  
Novolog Pharm-Up 1966 Ltd Reports Earnings Results for the Full Year Ended December 31, 2020 Marketscreener.com

Read at news.google.com
Google News at Macroaxis
  

Novolog Pharm Fundamental Analysis

We analyze Novolog Pharm's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Novolog Pharm using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Novolog Pharm based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.

Beta

Beta Comparative Analysis

Novolog Pharm is currently under evaluation in beta category among its peers. Beta is one of the most important measures of equity market volatility. Beta can be thought of as asset elasticity or sensitivity to market. In other words, it is a number that shows the relationship of an equity instrument to the financial market in which this instrument is traded. For example, if Beta of equity is 2, it is expected to significantly outperform market when the market is going up and significantly underperform when the market is going down. Similarly, Beta of 1 indicates that an asset and market will generate similar returns over time.

Novolog Pharm Up Potential Pair-trading

One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Novolog Pharm stock to make a market-neutral strategy. Peer analysis of Novolog Pharm could also be used in its relative valuation, which is a method of valuing Novolog Pharm by comparing valuation metrics with similar companies.

Complementary Tools for Novolog Stock analysis

When running Novolog Pharm's price analysis, check to measure Novolog Pharm's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Novolog Pharm is operating at the current time. Most of Novolog Pharm's value examination focuses on studying past and present price action to predict the probability of Novolog Pharm's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Novolog Pharm's price. Additionally, you may evaluate how the addition of Novolog Pharm to your portfolios can decrease your overall portfolio volatility.
Piotroski F Score
Get Piotroski F Score based on the binary analysis strategy of nine different fundamentals
Global Correlations
Find global opportunities by holding instruments from different markets
Commodity Channel
Use Commodity Channel Index to analyze current equity momentum
Watchlist Optimization
Optimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm